Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Products under Development by Stage of Development | 8 | 1 |
| Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Products under Development by Therapy Area | 9 | 1 |
| Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Products under Development by Indication | 10 | 2 |
| Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Products under Development by Companies | 14 | 2 |
| Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Therapeutics Assessment | 16 | 6 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Companies Involved in Therapeutics Development | 22 | 8 |
| Aeterna Zentaris Inc. | 22 | 1 |
| AGV Discovery, SAS | 23 | 1 |
| Asana BioSciences, LLC | 24 | 1 |
| Genentech, Inc. | 25 | 1 |
| Kura Oncology, Inc. | 26 | 1 |
| Laurent Pharmaceuticals Inc. | 27 | 1 |
| Merck &Co., Inc. | 28 | 1 |
| Merck KGaA | 29 | 1 |
| Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Drug Profiles | 30 | 11 |
| ASN-007 Drug Profile | 30 | 1 |
| CB-745 Drug Profile | 31 | 1 |
| fenretinide Drug Profile | 32 | 1 |
| JRP-890 Drug Profile | 33 | 1 |
| KO-947 Drug Profile | 34 | 1 |
| RG-7842 Drug Profile | 35 | 1 |
| SCH-722984 Drug Profile | 36 | 1 |
| Small Molecules to Inhibit ERK2 and Aurora B Kinase for Oncology Drug Profile | 37 | 1 |
| sprifermin Drug Profile | 38 | 2 |
| ulixertinib Drug Profile | 40 | 1 |
| Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Dormant Projects | 41 | 1 |
| Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Discontinued Products | 42 | 1 |
| Mitogen Activated Protein Kinase 1 (MAP Kinase 1 or MAPK 1 or Extracellular Signal Regulated Kinase 2 or ERK-2 or Protein Tyrosine Kinase ERK2 or EC 2.7.11.24) Featured News &Press Releases | 43 | 2 |
| Apr 14, 2016: Asana BioSciences, to Provide First Presentation of Pre-Clinical Data on its Novel ERK 1/2 Inhibitor Program at the American Association for Cancer Research Annual Meeting | 43 | 1 |
| Jun 15, 2015: Laurent Pharmaceuticals announces positive Phase 1b topline results for LAU-7b in Cystic Fibrosis | 43 | 1 |
| May 20, 2014: Laurent Pharmaceuticals announces initiation of a Phase 1 clinical study of Fenretinide in Cystic Fibrosis | 44 | 1 |
| Appendix | 45 | 2 |
| Methodology | 45 | 1 |
| Coverage | 45 | 1 |
| Secondary Research | 45 | 1 |
| Primary Research | 45 | 1 |
| Expert Panel Validation | 45 | 1 |
| Contact Us | 45 | 1 |
| Disclaimer | 46 | 1 |